Veradermics MANE Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year)

Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year) at other companies

Stifel FinancialSF

$25.99M-74.8%

Stifel FinancialSF

$178.83M+319%

Valley National BankVLY

$47.68M-25.9%

BKBK

$13.23B+23.7%

Valley National BankVLY

$3.52B+16.1%

BKBK

$61.66B+14.6%

Operating income-$29.9M-131%

Net income-$27.2M-120%

EPS (diluted)-$1.32+93.3%

Cash & equivalents$168.4M+419%

Total debt$4.0K—

Total equity$390.6M+744%

Total assets$397.4M—

Operating cash flow-$21.2M-59.0%

CapEx--100%

Free cash flow-$21.2M-58.7%

Market cap$3.92B—

Return on equity-28.7%—

Current ratio59.1×—

Reported directly by Veradermics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost.

The official record: Veradermics ’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Veradermics 's available-for-sale debt securities - amortized cost (due within one year)?: Veradermics (MANE) reported available-for-sale debt securities - amortized cost (due within one year) of $289.4M in Q1 2026.